Summary
I am an MRC Investigator (Programme Leader Track) working on the development and implementation of adaptive and Bayesian designs in clinical trials.
Currently, I actively work on the following topics:
Dose-Finding Trials
- A Ollier and P Mozgunov. On inclusion of covariates in model based dose finding clinical trial designs. Statistics in Medicine, 44(3-4):e10337, 2025.
- T Jaki, H Barnett, A Titman, and P Mozgunov. A seamless phase i/ii platform design with a time-to-event efficacy endpoint for potential covid-19 therapies. Statistical Methods in Medical Research, Epub, 2024.
Basket Trials
- L Daniells, P Mozgunov, H Barnett, A Bedding, and T Jaki. Incorporating historic information to further improve power when conducting Bayesian information borrowing in basket trials. Biostatistics, Accepted, 2025
- L Daniells, P Mozgunov, H Barnett, A Bedding, and T Jaki. How to add baskets to an ongoing basket trial with information borrowing. Statistical Methods in Medical Research, Epub, 2025.
Platform Trials
- P Greenstreet, T Jaki, A Bedding, and P Mozgunov. Design of platform trials with a change in the control treatment arm. Biometrics, Accepted, 2025
- P Greenstreet, T Jaki, A Bedding, C Harbron, and P Mozgunov. A multi-arm multi-stage platform design that allows preplanned addition of arms while still controlling the family-wise error. Statistics in Medicine, 43(19):3613–3632, 2024
Biomarker Trials
- A Serra, J Geronimi, S Guilleminot, H Hadjur, M-K Riviere, G Saint-Hilary, and P Mozgunov. A novel approach to assess the predictiveness of a continuous biomarker in early phases of drug development. Statistics in Medicine, Epub, 2025.
I am collaborating with >10 clinical trial units around the UK and have les the statistical design of over 20 trials. I have designed trials in oncology, psychological, cardiovascular, neurodivergent, infectious diseases as well as diabetes, stroke and rheumatology
I also consult a number of pharmaceutical and biotech companies on the development of novel adaptive designs and support their implementations in practice. My contributions in the dose-finding domain has resulted in shaping a regulatory guidance for dose optimisation.
The full list of funding, publications and professional activities can be found at ORCID.
Selected Grants
To date, I have been an applicant on 12 successful grants, In 2020, I was awarded a highly-prestigious personal 5-year NIHR Advanced Fellowship (£685k). All of these total to £14,296k external funding and £1,881k for which I am responsible for. Selected grants are listed below.
- PI: NIHR. Advanced Fellow, Bringing Innovative Early Phase Trials Methods to Practice. Role: development of novel statistical methods, support of CTUs with trials, outreach; £685k
- Co-I: CRUK CDD. Phase I/IIa trial of HTL0039732, as mono and in combo in solid tumours. Role: development of dose-finding design and its implementation
- Co-I: Rosetree. Treating behaviours in syndromes assoc with frontotemporal lobar degeneration. Role: development of basket design and its implementation, £708k;
- Co-I: BHF. Azacytidine Treatment Effect on hypertrophic Cardiomyopathy. Role: development of dose-finding design and its implementation, £464k;
- Co-I: Rosetree. Treating behaviours in syndromes assoc with frontotemporal lobar degeneration. Role: development of basket design and its implementation, £708k;
Selected Professional Activities
- Since Jan 2022: Panel Member for the Medical Research Council, Developmental Pathway Funding Scheme
- Since Jan 2025: Panel Member for the NIHR Pre-doctoral Award
- Since Apr 2025: Lead for Section Committee of NIHR Statistics Group: Early Phase Clinical Trials
